ML
FLNA

McAdam LLC’s Filana Therapeutics FLNA Stock Holding History

McAdam LLC’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,057
Closed -$208K – 371
2024
Q3 		$208K Buy
+7,057
New +$163K 0.01% 311
2023
Q1 		– Sell
-6,108
Closed -$267K – 276
2022
Q4 		$267K Sell
6,108
-82
-1% -$2.95K 0.03% 156
2022
Q3 		$259K Buy
+6,190
New +$167K 0.03% 186
2022
Q2 		– Sell
-6,209
Closed -$231K – 235
2022
Q1 		$231K Buy
6,209
+101
+2% +$4.28K 0.02% 188
2021
Q4 		$267K Sell
6,108
-259
-4% -$13.6K 0.03% 156
2021
Q3 		$395K Buy
6,367
+903
+17% +$75.4K 0.04% 114
2021
Q2 		$565K Buy
5,464
+106
+2% +$5.68K 0.06% 93
2021
Q1 		$241K Buy
+5,358
New +$211K 0.03% 143

Other funds holding FLNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

McAdam LLC's FLNA Position: Q4 2024 in Review

McAdam LLC sold out of Filana Therapeutics (FLNA) in Q4 2024, closing a stake of 7,057 shares — an estimated $208K sold.

McAdam LLC first reported a position in FLNA in Q1 2021 and held it in 8 quarters. The position peaked at $565K in Q2 2021. 137 funds tracked by Wall St. Rank hold FLNA as of Q4 2024.

  • McAdam LLC reported no remaining Filana Therapeutics position as of Q4 2024 after selling out during the quarter.
  • McAdam LLC sold 7,057 Filana Therapeutics shares in Q4 2024, an estimated $208K.
  • McAdam LLC first reported a position in Filana Therapeutics in Q1 2021 and held it in 8 quarters.
  • McAdam LLC's Filana Therapeutics position peaked at $565K in Q2 2021.
  • 137 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2024.

Based on McAdam LLC's 13F filing for Q4 2024, filed 24 Jan 2025.